{"success":true,"data":{"pressRelease":{"id":"27412","rtpr_id":"nGNX8yh5TX","ticker":"BOLD","exchange":"NASDAQ","all_tickers":["BOLD"],"title":"Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights","author":"Globe Newswire","published_at":"2026-05-08T11:00:00.445Z","article_body":"Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940\n\n$93 million in cash provides runway through expected clinical proof-of-concept\nreadout for KOMODO-1\n\nSAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio\n(https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==)\n(Nasdaq: BOLD), a clinical-stage oncology company interrogating\nextrachromosomal DNA (ecDNA) biology to deliver transformative therapies to\npatients with previously intractable oncogene amplified cancers, today\nannounced financial results and business highlights for the fiscal quarter\nended March 31, 2026.\n\n“We are encouraged by the progress of the KOMODO-1 trial,\" said Zachary\nHornby, President and Chief Executive Officer of Boundless Bio. “We continue\nto expand the body of evidence supporting BBI-940’s kinesin degradation\nmechanism, with our recent AACR poster demonstrating anti-tumor activity and\ntumor regression across multiple ecDNA+ cancer models. These findings further\nstrengthen our confidence in the therapeutic potential of BBI-940 as we\nadvance the program through a first-in-human clinical trial.”\n\nBusiness Highlights and Upcoming Milestones\n\nBBI-940 Novel Kinesin Degrader Clinical Program\n* Enrollment is ongoing in KOMODO-1 (Kinesin Oral Molecular Degrader for\nOncology-1), a first-in-human clinical trial of BBI-940 in patients with\nestrogen receptor positive and human epidermal growth factor receptor 2\nnegative (ER+/HER2-) breast cancer who have progressed following treatment\nwith a cyclin-dependent kinase 4 and/or 6 (CDK4/6) inhibitor plus endocrine\ntherapy, as well as patients with triple-negative breast cancer luminal\nandrogen receptor subtype (TNBC-LAR).\n* Initial safety and efficacy clinical proof-of-concept data are expected\nwithin the Company’s existing cash runway timeline.\nValidating Kinesin Degradation Data Presented at 2026 AACR Annual Meeting\n* In vitro and in vivo study data were presented at the American Association\nfor Cancer Research (AACR) Annual Meeting 2026, which demonstrated that\ngenetic depletion and pharmacologic degradation of a novel kinesin (Kinesin)\ncause ecDNA mis-segregation, ecDNA reduction, and reduced viability of ecDNA\npositive (ecDNA+) cancer cells.\n* Further, selective degradation of Kinesin in a panel of tumor cell lines\ndemonstrated sensitivity across multiple tumor types, including 32% of breast\ncancer cell lines, including those positive for ecDNA and FGFR1 gain. This\nmolecularly defined subgroup for Kinesin degradation sensitivity was further\nvalidated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+\nTNBC-LAR model, and significant antitumor activity as monotherapy and in\ncombination with fulvestrant in an ecDNA+/FGFR1+ ER+ breast cancer model.\nFirst Quarter 2026 Financial Results\n* Cash Position: Cash, cash equivalents, and short-term investments totaled\n$92.8 million as of March 31, 2026. The Company expects its cash to fund\noperations into the second half of 2028.\n* Research and Development (R&D) Expenses: R&D expenses were $9.7 million for\nthe first quarter of 2026 compared to $12.1 million for the same period in\n2025.\n* General and Administrative (G&A) Expenses: G&A expenses were $4.7 million\nfor the first quarter of 2026 compared to $5.2 million for the same period in\n2025.\n* Net Loss: Net loss totaled $13.6 million for the first quarter of 2026\ncompared to $15.8 million for the same period in 2025.\nAbout Boundless Bio\n\nBoundless Bio is a clinical-stage oncology company dedicated to unlocking a\nnew paradigm in cancer therapeutics that addresses the significant unmet need\nin patients with oncogene amplified tumors. Boundless Bio’s research focuses\non extrachromosomal DNA (ecDNA), a root cause of oncogene amplification\nobserved in 14% to 17% of cancer patients. Boundless Bio is developing\nBBI-940, a potentially first-in-class, oral, selective Kinesin degrader as an\necDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered\nin San Diego, California.\n\nFor more information, visit https://boundlessbio.com/and follow us\non LinkedIn\n(https://www.globenewswire.com/Tracker?data=-B5UtfYzpbHcpGH0ellaOmabZpMIoTkA10MQmcU56vWAiBe95S7rjIPEdyrz3ABlK42QIMIbbt3cruBYf35r3iUsBXZ91UZEER9wiwO3IXgoY4NKTRZ-kqQTQ86mUGJ1) and X\n(https://www.globenewswire.com/Tracker?data=xAtxt5O5JnDbrshe7UqV5zEjiLHFTfSJyea2nolDb9nYFnjpUO2bvMe722w9UB3Gpd6Kk8-PqyqcdriLQM7dyw==).\n\nForward-Looking Statements\n\nBoundless Bio, Inc. (the Company) cautions you that statements contained in\nthis press release that are not a description of historical facts are\nforward-looking statements. In some cases, you can identify forward-looking\nstatements by terms such as “anticipate,” “believe,”\n“contemplate,” “continue,” “could,” “estimate,” “expect,”\n“intend,” “may,” “plan,” “potential,” “predict,”\n“project,” “should,” “would,” “target,” or “will” or the\nnegative of these terms or other similar expressions. Forward-looking\nstatements are based on the Company’s current beliefs and expectations and\ninclude but are not limited to statements regarding: plans to continue\nenrollment in and advance the KOMODO-1 trial through initial clinical\nproof-of-concept data; the expected timing of an initial clinical\nproof-of-concept readout from the KOMODO-1 trial; the significance of data\nfrom preclinical studies of BBI-940; the Company’s cash runway and the\nsufficiency thereof to fund operations through the anticipated initial\nclinical proof-of-concept readout from the KOMODO-1 trial; the potential\nsafety and therapeutic benefits of BBI-940 as a monotherapy and in combination\nwith fulvestrant; and BBI-940’s potential to become a first-in-class drug\nproduct. The Company’s actual results and performance may differ materially\nfrom those expressed or implied in any forward-looking statement due to\nsubstantial known and unknown risks and uncertainties, including, without\nlimitation: potential delays in the enrollment, data readouts, or completion\nof clinical trials or in regulatory submissions and responses; the Company may\nuse its capital resources sooner than it expects; the Company may be unable to\nobtain necessary additional funding when needed, on acceptable terms, or at\nall; the Company is early in its development efforts and its approach to\ndiscover and develop ecDTx to treat oncogene amplified cancers is novel and\nunproven; clinical and preclinical development of therapeutics involves a\nlengthy and expensive process with inherently uncertain timelines and\noutcomes; results from preclinical studies or early clinical trials not\nnecessarily being predictive of future results; unexpected adverse side\neffects or other safety risks or inadequate efficacy of the Company’s ecDTx\nthat may delay or limit their development, regulatory approval, and/or\ncommercialization; the Company’s ability to retain key personnel; the\nCompany’s dependence on third parties in connection with clinical trials,\npreclinical studies, and manufacturing; the Company may expend its limited\nresources to pursue a particular ecDTx or combination therapy and fail to\ncapitalize on ecDTx with greater development or commercial potential; the\npotential for the Company’s programs and prospects to be negatively impacted\nby developments relating to its competitors, including the results of studies\nor regulatory determinations relating to its competitors; regulatory and\nhealthcare reform developments in the United States and foreign countries;\ndisruptions or changes at the U.S. Food and Drug Administration (FDA) or other\ngovernment agencies that limit the FDA’s ability to perform routine\nactivities or function in the normal course or impact the regulatory approval\npathway or commercial potential for the Company’s ecDTx; the Company’s\nability to obtain, maintain, defend, and enforce patent or other intellectual\nproperty protection for its ecDTx and technology; macroeconomic and\ngeopolitical events and conditions, including international trade policies and\ntariffs, military conflicts, inflation, supply chain disruptions, market\nvolatility, slowed economic growth or recession; and other risks described in\nthe Company’s filings with the Securities and Exchange Commission (SEC),\nincluding under the heading “Risk Factors” in the Company’s annual\nreport on Form 10-K for the year ended December 31, 2025 and any subsequent\nfilings with the SEC. You are cautioned not to place undue reliance on\nforward-looking statements, which speak only as of the date hereof, and,\nexcept as required by law, the Company undertakes no obligation to update such\nstatements to reflect events that occur or circumstances that exist after the\ndate hereof. All forward-looking statements are qualified in their entirety by\nthis cautionary statement, which is made under the safe harbor provisions of\nthe Private Securities Litigation Reform Act of 1995.\n\nInvestor Contacts:\nJames Lee, Boundless Bio\njlee@boundlessbio.com\n \nJon Nugent, THRUST\njon@thrustsc.com\n\nMedia Contact:\nCarly Scaduto, THRUST\ncarly@thrustsc.com\n\n BOUNDLESS BIO, INC.                                                                                                                  \n Financial Information (Unaudited)                                                                                                    \n                                                                                                                                      \n                                                                                                                                      \n                                                                                                                                      \n Condensed Statements of Operations Data:                                          Three Months Ended March 31,                       \n (In thousands, except per share amounts)                                          2026                          2025                 \n Operating expenses:                                                                                                                  \n Research and development                                                          $      9,734                  $        12,138      \n General and administrative                                                               4,741                           5,203       \n Total operating expenses                                                                 14,475                          17,341      \n Loss from operations                                                                     (14,475  )                      (17,341  )  \n Other income, net:                                                                                                                   \n Interest income                                                                          920                             1,585       \n Other expense                                                                            —                               (2       )  \n Total other income, net                                                                  920                             1,583       \n Net loss                                                                          $      (13,555  )             $        (15,758  )  \n Net loss per share, basic and diluted                                             $      (0.60    )             $        (0.71    )  \n Weighted-average shares used in calculation                                              22,407                          22,300      \n                                                                                                                                      \n Condensed Balance Sheet Data:                                                     March 31,                     December 31,         \n (In thousands)                                                                    2026                          2025                 \n Cash, cash equivalents, and short-term investments                                $      92,847                 $        107,581     \n Total assets                                                                      $      140,970                $        157,059     \n Total liabilities                                                                 $      54,587                 $        58,405      \n Accumulated deficit                                                               $      273,224                $        259,669     \n Total stockholders' equity                                                        $      86,383                 $        98,654      \n Working capital (1)                                                               $      85,033                 $        97,074      \n __________                                                                                                                           \n (1) We define working capital as current assets less current liabilities.                                                            \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3b8ff619-e7af-4c58-a7f2-de0c4019068d)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8yh5TX","title":"Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights","author":"Globe Newswire","ticker":"BOLD","created":"2026-05-08T11:00:00.445Z","tickers":["BOLD"],"exchange":"NASDAQ","article_body":"Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940\n\n$93 million in cash provides runway through expected clinical proof-of-concept\nreadout for KOMODO-1\n\nSAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio\n(https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==)\n(Nasdaq: BOLD), a clinical-stage oncology company interrogating\nextrachromosomal DNA (ecDNA) biology to deliver transformative therapies to\npatients with previously intractable oncogene amplified cancers, today\nannounced financial results and business highlights for the fiscal quarter\nended March 31, 2026.\n\n“We are encouraged by the progress of the KOMODO-1 trial,\" said Zachary\nHornby, President and Chief Executive Officer of Boundless Bio. “We continue\nto expand the body of evidence supporting BBI-940’s kinesin degradation\nmechanism, with our recent AACR poster demonstrating anti-tumor activity and\ntumor regression across multiple ecDNA+ cancer models. These findings further\nstrengthen our confidence in the therapeutic potential of BBI-940 as we\nadvance the program through a first-in-human clinical trial.”\n\nBusiness Highlights and Upcoming Milestones\n\nBBI-940 Novel Kinesin Degrader Clinical Program\n* Enrollment is ongoing in KOMODO-1 (Kinesin Oral Molecular Degrader for\nOncology-1), a first-in-human clinical trial of BBI-940 in patients with\nestrogen receptor positive and human epidermal growth factor receptor 2\nnegative (ER+/HER2-) breast cancer who have progressed following treatment\nwith a cyclin-dependent kinase 4 and/or 6 (CDK4/6) inhibitor plus endocrine\ntherapy, as well as patients with triple-negative breast cancer luminal\nandrogen receptor subtype (TNBC-LAR).\n* Initial safety and efficacy clinical proof-of-concept data are expected\nwithin the Company’s existing cash runway timeline.\nValidating Kinesin Degradation Data Presented at 2026 AACR Annual Meeting\n* In vitro and in vivo study data were presented at the American Association\nfor Cancer Research (AACR) Annual Meeting 2026, which demonstrated that\ngenetic depletion and pharmacologic degradation of a novel kinesin (Kinesin)\ncause ecDNA mis-segregation, ecDNA reduction, and reduced viability of ecDNA\npositive (ecDNA+) cancer cells.\n* Further, selective degradation of Kinesin in a panel of tumor cell lines\ndemonstrated sensitivity across multiple tumor types, including 32% of breast\ncancer cell lines, including those positive for ecDNA and FGFR1 gain. This\nmolecularly defined subgroup for Kinesin degradation sensitivity was further\nvalidated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+\nTNBC-LAR model, and significant antitumor activity as monotherapy and in\ncombination with fulvestrant in an ecDNA+/FGFR1+ ER+ breast cancer model.\nFirst Quarter 2026 Financial Results\n* Cash Position: Cash, cash equivalents, and short-term investments totaled\n$92.8 million as of March 31, 2026. The Company expects its cash to fund\noperations into the second half of 2028.\n* Research and Development (R&D) Expenses: R&D expenses were $9.7 million for\nthe first quarter of 2026 compared to $12.1 million for the same period in\n2025.\n* General and Administrative (G&A) Expenses: G&A expenses were $4.7 million\nfor the first quarter of 2026 compared to $5.2 million for the same period in\n2025.\n* Net Loss: Net loss totaled $13.6 million for the first quarter of 2026\ncompared to $15.8 million for the same period in 2025.\nAbout Boundless Bio\n\nBoundless Bio is a clinical-stage oncology company dedicated to unlocking a\nnew paradigm in cancer therapeutics that addresses the significant unmet need\nin patients with oncogene amplified tumors. Boundless Bio’s research focuses\non extrachromosomal DNA (ecDNA), a root cause of oncogene amplification\nobserved in 14% to 17% of cancer patients. Boundless Bio is developing\nBBI-940, a potentially first-in-class, oral, selective Kinesin degrader as an\necDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered\nin San Diego, California.\n\nFor more information, visit https://boundlessbio.com/and follow us\non LinkedIn\n(https://www.globenewswire.com/Tracker?data=-B5UtfYzpbHcpGH0ellaOmabZpMIoTkA10MQmcU56vWAiBe95S7rjIPEdyrz3ABlK42QIMIbbt3cruBYf35r3iUsBXZ91UZEER9wiwO3IXgoY4NKTRZ-kqQTQ86mUGJ1) and X\n(https://www.globenewswire.com/Tracker?data=xAtxt5O5JnDbrshe7UqV5zEjiLHFTfSJyea2nolDb9nYFnjpUO2bvMe722w9UB3Gpd6Kk8-PqyqcdriLQM7dyw==).\n\nForward-Looking Statements\n\nBoundless Bio, Inc. (the Company) cautions you that statements contained in\nthis press release that are not a description of historical facts are\nforward-looking statements. In some cases, you can identify forward-looking\nstatements by terms such as “anticipate,” “believe,”\n“contemplate,” “continue,” “could,” “estimate,” “expect,”\n“intend,” “may,” “plan,” “potential,” “predict,”\n“project,” “should,” “would,” “target,” or “will” or the\nnegative of these terms or other similar expressions. Forward-looking\nstatements are based on the Company’s current beliefs and expectations and\ninclude but are not limited to statements regarding: plans to continue\nenrollment in and advance the KOMODO-1 trial through initial clinical\nproof-of-concept data; the expected timing of an initial clinical\nproof-of-concept readout from the KOMODO-1 trial; the significance of data\nfrom preclinical studies of BBI-940; the Company’s cash runway and the\nsufficiency thereof to fund operations through the anticipated initial\nclinical proof-of-concept readout from the KOMODO-1 trial; the potential\nsafety and therapeutic benefits of BBI-940 as a monotherapy and in combination\nwith fulvestrant; and BBI-940’s potential to become a first-in-class drug\nproduct. The Company’s actual results and performance may differ materially\nfrom those expressed or implied in any forward-looking statement due to\nsubstantial known and unknown risks and uncertainties, including, without\nlimitation: potential delays in the enrollment, data readouts, or completion\nof clinical trials or in regulatory submissions and responses; the Company may\nuse its capital resources sooner than it expects; the Company may be unable to\nobtain necessary additional funding when needed, on acceptable terms, or at\nall; the Company is early in its development efforts and its approach to\ndiscover and develop ecDTx to treat oncogene amplified cancers is novel and\nunproven; clinical and preclinical development of therapeutics involves a\nlengthy and expensive process with inherently uncertain timelines and\noutcomes; results from preclinical studies or early clinical trials not\nnecessarily being predictive of future results; unexpected adverse side\neffects or other safety risks or inadequate efficacy of the Company’s ecDTx\nthat may delay or limit their development, regulatory approval, and/or\ncommercialization; the Company’s ability to retain key personnel; the\nCompany’s dependence on third parties in connection with clinical trials,\npreclinical studies, and manufacturing; the Company may expend its limited\nresources to pursue a particular ecDTx or combination therapy and fail to\ncapitalize on ecDTx with greater development or commercial potential; the\npotential for the Company’s programs and prospects to be negatively impacted\nby developments relating to its competitors, including the results of studies\nor regulatory determinations relating to its competitors; regulatory and\nhealthcare reform developments in the United States and foreign countries;\ndisruptions or changes at the U.S. Food and Drug Administration (FDA) or other\ngovernment agencies that limit the FDA’s ability to perform routine\nactivities or function in the normal course or impact the regulatory approval\npathway or commercial potential for the Company’s ecDTx; the Company’s\nability to obtain, maintain, defend, and enforce patent or other intellectual\nproperty protection for its ecDTx and technology; macroeconomic and\ngeopolitical events and conditions, including international trade policies and\ntariffs, military conflicts, inflation, supply chain disruptions, market\nvolatility, slowed economic growth or recession; and other risks described in\nthe Company’s filings with the Securities and Exchange Commission (SEC),\nincluding under the heading “Risk Factors” in the Company’s annual\nreport on Form 10-K for the year ended December 31, 2025 and any subsequent\nfilings with the SEC. You are cautioned not to place undue reliance on\nforward-looking statements, which speak only as of the date hereof, and,\nexcept as required by law, the Company undertakes no obligation to update such\nstatements to reflect events that occur or circumstances that exist after the\ndate hereof. All forward-looking statements are qualified in their entirety by\nthis cautionary statement, which is made under the safe harbor provisions of\nthe Private Securities Litigation Reform Act of 1995.\n\nInvestor Contacts:\nJames Lee, Boundless Bio\njlee@boundlessbio.com\n \nJon Nugent, THRUST\njon@thrustsc.com\n\nMedia Contact:\nCarly Scaduto, THRUST\ncarly@thrustsc.com\n\n BOUNDLESS BIO, INC.                                                                                                                  \n Financial Information (Unaudited)                                                                                                    \n                                                                                                                                      \n                                                                                                                                      \n                                                                                                                                      \n Condensed Statements of Operations Data:                                          Three Months Ended March 31,                       \n (In thousands, except per share amounts)                                          2026                          2025                 \n Operating expenses:                                                                                                                  \n Research and development                                                          $      9,734                  $        12,138      \n General and administrative                                                               4,741                           5,203       \n Total operating expenses                                                                 14,475                          17,341      \n Loss from operations                                                                     (14,475  )                      (17,341  )  \n Other income, net:                                                                                                                   \n Interest income                                                                          920                             1,585       \n Other expense                                                                            —                               (2       )  \n Total other income, net                                                                  920                             1,583       \n Net loss                                                                          $      (13,555  )             $        (15,758  )  \n Net loss per share, basic and diluted                                             $      (0.60    )             $        (0.71    )  \n Weighted-average shares used in calculation                                              22,407                          22,300      \n                                                                                                                                      \n Condensed Balance Sheet Data:                                                     March 31,                     December 31,         \n (In thousands)                                                                    2026                          2025                 \n Cash, cash equivalents, and short-term investments                                $      92,847                 $        107,581     \n Total assets                                                                      $      140,970                $        157,059     \n Total liabilities                                                                 $      54,587                 $        58,405      \n Accumulated deficit                                                               $      273,224                $        259,669     \n Total stockholders' equity                                                        $      86,383                 $        98,654      \n Working capital (1)                                                               $      85,033                 $        97,074      \n __________                                                                                                                           \n (1) We define working capital as current assets less current liabilities.                                                            \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3b8ff619-e7af-4c58-a7f2-de0c4019068d)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-08T11:00:00.54150599Z","server_sent_at_ms":1778238000541},"received_at":"2026-05-08T11:00:00.681Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}